Leidos Awarded $44 Million Contract by the Centers for Disease Control and Prevention

Company to Provide Development, Support and Maintenance of the National Healthcare Safety Network

News provided by

Jul 30, 2014, 07:50 ET

RESTON, Va., July 30, 2014 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health and engineering solutions company, was awarded a prime task order by the Centers for Disease Control and Prevention (CDC) to provide development, support and maintenance of the National Healthcare Safety Network (NHSN). The single-award time and materials task order has a one-year base period of performance, four one-year options and a total contract value of approximately $44 million if all options are exercised. Work will be performed in Atlanta, Ga.

The NHSN is the nation's most widely used healthcare-associated infection (HAI) tracking system, providing facilities, states, regions and the nation with data needed to identify problem areas, measure progress of prevention efforts and ultimately eliminate HAIs. Under the task order, Leidos will provide development, support and maintenance of NHSN, including: testing, maintenance and development of the application; level one user support; technical architecture and design; electronic messaging processing and support; and development, deployments, system documentation and all other deliverables consistent with the CDC Enterprise Project Life Cycle guidelines.

"The CDC's efforts with the National Healthcare Safety Network are a priority for the nation, and we are proud to continue our support in building a healthcare surveillance system that enables public health officials across the country to make more informed decisions and improve health outcomes for our citizens," said President of Leidos Health Steve Comber.

About Leidos Health
As a leader for more than 25 years in the healthcare industry, Leidos Health fuses some of the world's most advanced technologies with the brightest minds in science, research and consulting. Today, Leidos Health is focused on developing next-generation solutions in areas such as biomedical research, public health and health analytics to turn data into actionable information for clinicians and their patients. From leading groundbreaking medical research to fighting diseases such as cancer, AIDS and malaria, to implementing and optimizing electronic health records that enhance the research process and improve critical efficiencies – Leidos Health's passion to improve patient care and reduce costs is helping to transform healthcare. For more information, visit www.Leidos.com/health.

About Leidos
Leidos is a FORTUNE 500^® science and technology solutions leader working to address some of the world's toughest challenges in national security, health and engineering. The Company's 22,000 employees support vital missions for our government and the commercial sector, develop innovative solutions to drive better outcomes and defend our Nation's digital and physical infrastructure from 'new world' threats. Headquartered in Reston, Va., Leidos reported annual revenues of approximately $5.77 billion for its fiscal year ended January 31, 2014 after giving effect to the spin-off of the company's technical services and information technology business. For more information, visit www.Leidos.com.

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 31, 2014, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.